Hormone Receptors in Breast Cancer Treatment

Why Hormone Receptor Profiling Matters No two breast cancers are exactly alike. A diagnosis of breast cancer is only the beginning — the pathology report that follows contains critical information that guides every subsequent treatment decision. One of the most important parts of that report is hormone receptor status . What Your Pathology Report Contains A comprehensive breast biopsy or mastectomy report from TSL includes: Whether the cancer is non invasive or invasive Histologic type and cell grade Tumour size and surgical margins Lymphatic or vascular system invasion Lymph node involvement Hormone receptor status ER and PR HER2 status TSL uses a synoptic reporting template — the same standardised format used by leading cancer centres worldwide — so your oncologist receives a report they can act on immediately. Breast biopsy and mastectomy reports are available within five working days . ER, PR, and HER2 Testing at TSL Oestrogen Receptor ER and Progesterone Receptor PR ER and PR positive cancers respond to hormone blocking therapies such as tamoxifen and aromatase inhibitors. TSL performs in house automated immunohistochemistry IHC for ER and PR analysis — results are reported within two weeks of the initial biopsy report. HER2 Testing HER2 positive cancers are aggressive but respond well to targeted agents such as trastuzumab Herceptin . TSL provides: In house IHC for HER2 screening reported as 0, 1+, 2+, or 3+ FISH testing for indeterminate 2+ cases, performed in partnership with specialist overseas laboratories Oncotype DX For ER positive, HER2 negative early stage bre

Hormone Receptors in Breast Cancer Treatment — TSL Pathology